BMY Q4 2024 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$124B

Q4 2024 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$12.3B+7.5% YoY

Gross Profit

$7.4B60.2% margin

Operating Income

$2.5B20.5% margin

Net Income

$72M0.6% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

+3.8%

Cash Flow

Operating Cash Flow

$4.4B

Free Cash Flow

$4.1B

Stock-Based Comp.

$120M

Balance Sheet

Total Assets

$92.6B

Total Liabilities

$76.2B

Stockholders' Equity

$16.3B

Cash & Equivalents

$10.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12.3B	$11.5B	+7.5%
Gross Profit	$7.4B	$6.5B	+14.4%
Operating Income	$2.5B	$2.0B	+29.7%
Net Income	$72M	$1.8B	-95.9%

Revenue Segments

Eliquis

$3.2B26%

Opdivo

$2.5B20%

Revlimid

$1.3B11%

Orencia

$1.0B8%

Pomalyst/Imnovid

$823M7%

Yervoy

$675M5%

Reblozyl

$547M4%

Other Growth Brands

$512M4%

Breyanzi

$263M2%

Opdualag

$254M2%

Other Legacy Brands

$250M2%

Camzyos

$223M2%

Sprycel

$198M2%

Abraxane

$174M1%

Zeposia

$158M1%

Abecma

$105M1%

Sotyktu

$83M1%

Krazati

$39M0%

Geographic Segments

UNITED STATES

$8.6B70%

Rest Of World

$3.4B28%

Other Region

$350M3%